You are here

Article Text

Article menu

Download PDFPDF

Plenary sessions
Plenary 6
IGCS19-0392
37 Reducing overtreatment of early stage ovarian cancer: strategies implementation by a mirna-driven prognostic assessment
Free
  1. A Ditto1,
  2. F Raspagliesi1,
  3. U Leone Roberti Maggiore1,
  4. V Chiappa1,
  5. G Bogani1,
  6. V Liberale1,
  7. MT Evangelista1,
  8. C Sonetto1,
  9. G Maltese1,
  10. F Zanaboni1,
  11. ML Carcangiu2,
  12. B Paolini2,
  13. D Mezzanzanica3,
  14. P Alberti3,
  15. F Murgia1,
  16. A Tomassetti3,
  17. L De Cecco4,
  18. A Devecchi4 and
  19. M Bagnoli3
  1. 1IRCCS Foundation National Cancer Institute, Department of Gynecologic Oncology, Milan, Italy
  2. 2IRCCS Foundation National Cancer Institute, Department of Diagnostic Pathology and Laboratory, Milan, Italy
  3. 3IRCCS Foundation National Cancer Institute, Unit of Molecular Therapies- Department of Research, Milan, Italy
  4. 4IRCCS Foundation National Cancer Institute, Integrated Biology Platform- Department of Applied Research and Technology Development, Milan, Italy

Abstract

Objectives About 30% of Epithelial Ovarian Cancer (EOC) patients present with early-stage disease (FIGO stage I–II). However, in spite of the generally favourable prognosis, eEOC have heterogeneous risk of relapse, ranging from 13% to over 40% in various reports. We previously identified 35 miRNAs that predicted risk of progression or relapse in advanced EOC and used them to create a prognostic model, the 35-miRNA-based predictor of Risk of Ovarian Cancer Relapse or progression (MiROvaR). The aim of the current study is to test MiROvaR performance to predict risk of progression or relapse in patients with eEOC.

Methods Patients with eEOC who underwent primary surgery at our Institution between 1994 and 2014 were included. The primary endpoint was progression-free survival. In particular, it was assessed the ability of MiROvaR to predict progression-free survival with Kaplan-Meier curves and the log-rank test.

Results A total of 80 patients were included in the study with a median follow-up time of 68.2 months (CI: 61.3–80.7). MiROVaR classified 37 patients (46.3%) at high-risk (14 events, median PFS: 117 months, 95%CI: 62-nyr) and 43 patients (53.7%) at low-risk of relapse (2 events, median PFS time: nyr; 95%CI:nyr). Kaplan-Meier curves confirmed the significantly different PFS time (figure 1) for the two groups with HR=10.13 (95%CI: 2.3–4.4, p=0.00015) for the high-risk patients.

Abstract 37 Figure 1
Abstract 37 Figure 1

Kaplan-Meier curves of PFS in eEOC cohort according to MiROvaR classification

Conclusions MiROvaR confirmed as a potential predictor of EOC progression and has prognostic value independent of relevant clinical covariates also in patients with eEOC. MiROvaR warrants further investigation for the development of a clinical-grade prognostic assay.

https://doi.org/10.1136/ijgc-2019-IGCS.37

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.